Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination

Rituximab and COVID‐19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Victoria S., Lin, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365555/
https://www.ncbi.nlm.nih.gov/pubmed/34429981
http://dx.doi.org/10.1002/ccr3.4517
_version_ 1783738731963875328
author Leung, Victoria S.
Lin, Yuankai
author_facet Leung, Victoria S.
Lin, Yuankai
author_sort Leung, Victoria S.
collection PubMed
description Rituximab and COVID‐19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the timing of rituximab infusion and vaccination are urgently needed.
format Online
Article
Text
id pubmed-8365555
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-83655552021-08-23 Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination Leung, Victoria S. Lin, Yuankai Clin Case Rep Case Report Rituximab and COVID‐19 vaccine can cause massive hyperacute depletion of B cells and plasma cells, as well as subsequent cytokine release syndrome, coagulopathy, and pancytopenia. These effects differ from the adverse effects that have been reported for rituximab, and new guidelines regarding the timing of rituximab infusion and vaccination are urgently needed. John Wiley and Sons Inc. 2021-08-16 /pmc/articles/PMC8365555/ /pubmed/34429981 http://dx.doi.org/10.1002/ccr3.4517 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
Leung, Victoria S.
Lin, Yuankai
Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
title Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
title_full Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
title_fullStr Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
title_full_unstemmed Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
title_short Rituximab‐induced acute lympholysis and pancytopenia after COVID‐19 vaccination
title_sort rituximab‐induced acute lympholysis and pancytopenia after covid‐19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365555/
https://www.ncbi.nlm.nih.gov/pubmed/34429981
http://dx.doi.org/10.1002/ccr3.4517
work_keys_str_mv AT leungvictorias rituximabinducedacutelympholysisandpancytopeniaaftercovid19vaccination
AT linyuankai rituximabinducedacutelympholysisandpancytopeniaaftercovid19vaccination

Ejemplares similares